Merck Sharp & Dohme LLC has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS G12D mutant-targeting moiety via a linker reported to be useful for the treatment of cancer.